Transthyretin as a potential biomarker for the differential diagnosis between lung cancer and lung infection

Ding,Hongmei; Liu,Jianhua; Xue,Rong; Zhao,Peng; Qin,Yi; Zheng,Fang; Sun,Xuguo

doi:10.3892/br.2014.313

Transthyretin as a potential biomarker for the differential diagnosis between lung cancer and lung infection

Authors:
- Hongmei Ding
- Jianhua Liu
- Rong Xue
- Peng Zhao
- Yi Qin
- Fang Zheng
- Xuguo Sun
View Affiliations

Affiliations: School of Laboratory Medicine, Tianjin Medical University, Tianjin 300203, P.R. China, The Second Hospital of Tangshan, Tangshan, Hebei 063000, P.R. China, General Hospital of Tianjin Medical University, Tianjin 300052, P.R. China
Published online on: July 11, 2014 https://doi.org/10.3892/br.2014.313
Pages: 765-769

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Satisfactory biomarkers for screening and early diagnosis of lung cancer remain scarce and require further investigation. The aim of the present study was to examine the changes of the biochemical and protein composition in the serum and pleural effusion from lung cancer and lung infection (bacterial pneumonia) patients. A total of 92 patients with lung cancer, 38 with bacterial pneumonia and 42 healthy controls were enrolled in the study. The serum levels of cholesterol, apolipoprotein A and transthyretin (TTR) in the lung cancer patients were higher than that of the lung infection patients (P<0.05). The levels of TTR were higher, whereas the activity of adenosine deaminase (ADA) was lower in the pleural effusion from the lung cancer patients compared to the lung infection patients (P<0.05). Furthermore, the pleural effusion/serum TTR ratios in the lung cancer patients were higher, whereas the ratios of ADA were lower (P<0.05). By matrix‑assisted laser desorption/ionization time‑of‑flight mass spectrometry analysis, four major peaks corresponding to native TTR, Sul‑TTR, Cys‑TTR and Cysgly‑TTR were observed in the serum of the lung cancer and lung infection patients. A significant increase was found in the proportion of Cysgly‑TTR in the pleural effusion from the patients with lung cancer. The data indicated that a combination of pleural effusion/serum TTR ratios and modified TTR may be beneficial for the differential diagnosis between lung cancer and lung infection.

View Figures

View References

1	Spira A and Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med. 350:379–392. 2004. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403. 2013. View Article : Google Scholar : PubMed/NCBI
3	Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 46:765–781. 2010. View Article : Google Scholar : PubMed/NCBI
4	Schneider J: Tumor markers in detection of lung cancer. Adv Clin Chem. 42:1–41. 2006. View Article : Google Scholar : PubMed/NCBI
5	Harmsma M, Schutte B and Ramaekers FC: Serum markers in small cell lung cancer: opportunities for improvement. Biochim Biophys Acta. 1836.255–272. 2013.
6	Chu XY, Hou XB, Song WA, Xue ZQ, Wang B and Zhang LB: Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer in patients with suspicious pulmonary masses: a single center analysis. Cancer Biol Ther. 11:995–1000. 2011. View Article : Google Scholar : PubMed/NCBI
7	Kley K and Oehr P: Usefulness of combined FDG-PET with CT or tumour markers in lung cancer diagnosis. Anticancer Res. 30:1741–1745. 2010.PubMed/NCBI
8	Grunnet M and Sorensen JB: Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 76:138–143. 2012. View Article : Google Scholar : PubMed/NCBI
9	Witze ES, Old WM, Resing KA and Ahn NG: Mapping protein post-translational modifications with mass spectrometry. Nat Methods. 4:798–806. 2007. View Article : Google Scholar : PubMed/NCBI
10	Zhukov TA, Johanson RA, Cantor AB, Clark RA and Tockman MS: Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer. 40:267–279. 2003. View Article : Google Scholar : PubMed/NCBI
11	Howard BA, Wang MZ, Campa MJ, Corro C, Fitzgerald MC and Patz EF Jr: Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. Proteomics. 3:1720–1724. 2003. View Article : Google Scholar
12	Yang SY, Xiao XY, Zhang WG, et al: Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer. 5:832005. View Article : Google Scholar : PubMed/NCBI
13	Indovina P, Marcelli E, Pentimalli F, Tanganelli P, Tarro G and Giordano A: Mass spectrometry-based proteomics: the road to lung cancer biomarker discovery. Mass Spectrom Rev. 32:129–142. 2013. View Article : Google Scholar : PubMed/NCBI
14	Maciel CM, Junqueira M, Paschoal ME, Kawamura MT, Duarte RL, Carvalho Mda G and Domont GB: Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients. J Exp Ther Oncol. 5:31–38. 2005.PubMed/NCBI
15	Liu L, Liu J, Dai S, et al: Reduced transthyretin expression in sera of lung cancer. Cancer Sci. 98:1617–1624. 2007. View Article : Google Scholar : PubMed/NCBI
16	Liu L, Liu J, Wang Y, et al: A combined biomarker pattern improves the discrimination of lung cancer. Biomarkers. 16:20–30. 2011. View Article : Google Scholar : PubMed/NCBI
17	Lim A, Sengupta S, McComb ME, Théberge R, Wilson WG, Costello CE and Jacobsen DW: In vitro and in vivo interactions of homocysteine with human plasma transthyretin. J Biol Chem. 278:49707–49713. 2003. View Article : Google Scholar : PubMed/NCBI
18	Connors LH, Lim A, Prokaeva T, Roskens VA and Costello CE: Tabulation of human transthyretin (TTR) variants, 2003. Amyloid. 10:160–184. 2003. View Article : Google Scholar : PubMed/NCBI
19	Ingenbleek Y and Young VR: Significance of transthyretin in protein metabolism. Clin Chem Lab Med. 40:1281–1291. 2002. View Article : Google Scholar : PubMed/NCBI
20	Potter MA and Luxton G: Transthyretin measurement as a screening tool for protein calorie malnutrition in emergency hospital admissions. Clin Chem Lab Med. 40:1349–1354. 2002. View Article : Google Scholar
21	Schweigert FJ and Sehouli J: Transthyretin, a biomarker for nutritional status and ovarian cancer. Cancer Res. 65:11142005.PubMed/NCBI
22	Buxbaum JN: The systemic amyloidoses. Curr Opin Rheumatol. 16:67–75. 2004. View Article : Google Scholar
23	Buxbaum JN and Reixach N: Transthyretin: the servant of many masters. Cell Mol Life Sci. 66:3095–3101. 2009. View Article : Google Scholar : PubMed/NCBI
24	Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S and Farias-Eisner R: Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics. 5:4589–4596. 2005. View Article : Google Scholar : PubMed/NCBI
25	Farias-Eisner G, Su F, Robbins T, Kotlerman J, Reddy S and Farias-Eisner R: Validation of serum biomarkers for detection of early- and late-stage endometrial cancer. Am J Obstet Gynecol. 202:73.e1–73.e5. 2010. View Article : Google Scholar : PubMed/NCBI
26	Travis WD, Colby TV, Corrin B, et al: Histological Typing of Lung and Pleural Tumours. 3rd edition. Springer; Berlin: 1999, View Article : Google Scholar
27	Heinold A, Kuehl B, Brenner-Weiss G, Opelz G and Tran TH: Sequential analysis by immunoprecipitation-MALDI-TOF: a novel method for detection and identification of alloantibody specificities. Hum Immunol. 71:462–467. 2010. View Article : Google Scholar : PubMed/NCBI
28	Grus FH, Joachim SC, Sandmann S, Thiel U, Bruns K, Lackner KJ and Pfeiffer N: Transthyretin and complex protein pattern in aqueous humor of patients with primary open-angle glaucoma. Mol Vis. 14:1437–1445. 2008.PubMed/NCBI
29	Wang Z, Wang C, Huang X, Shen Y, Shen J and Ying K: Differential proteome profiling of pleural effusions from lung cancer and benign inflammatory disease patients. Biochim Biophys Acta. 1824.692–700. 2012.PubMed/NCBI